glp 1 drugs and crohn's disease Primer: The Skinny on GLP-1s GLP-1R Agonists and Their Therapeutic

Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial

Read Part 2 here

Common causes include infectious diseases (e.g., bacterial or viral infections), metabolic disorders (e.g., diabetic cardiomyopathy [DC], and amyloid-related myocardial changes), endocrine disorders (e.g., hyperthyroidism or hypothyroidism), connective tissue diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus), ischemic heart diseases (e.g., coronary atherosclerosis, coronary vasospasm), hypersensitivity reactions (e.g., allergic responses to penicillin or sulfonamide drugs), and toxic injuries (e.g., myocardial damage caused by bacterial toxins in typhoid fever)

[DOI] [PubMed] [Google Scholar] 63.Zhang L., Li C., Zhang Z., Zhang Z., Jin Q.Q., Li L., Hlscher C

Common strategies for extending the duration of GLP-1 RAs include: Amino Acid Sequence Optimization : Reducing rapid degradation by DPP-4 enzymes to extend the drug's half-life

The difference is how the product is built